

Supplemental Material

Supplemental Table 1: Baseline characteristics of dabigatran and rivaroxaban patients with their matched warfarin control

	Warfarin	Dabigatran	Warfarin	Rivaroxaban
n	448	224	412	206
age (years)	69.7	68.5	68.6	67.1
gender (%male)	56.5	56.5	59.3	59.3
Caucasian (%)	83.5	83.5	74.6	74.6
diabetic (%)	74.1	74.1	68.9	68.9
time on HD (years)	2.3	2.1	2.2	2.3
catheter (%)	31.7	31.7	20.0	20.0
systolic BP (mmHg)	130	129	134	136
diastolic BP (mmHg)	68	67	70	69
albumin (g/dL)	3.6	3.6	3.6	3.6
hemoglobin (g/dL)	10.7	10.8	10.6	10.4
thrombocytopenia (%)	0	0	0	0
Epogen (units per HD)	6082	6908	4975	5271
heparin (units per HD)	3624	4076	3247	3570
aspirin (%)	2.2	2.2	2.4	2.4
Charlson score	5.4	5.5	5.3	5.6
CHADS ₂ score	2.3	2.3	2.2	2.2
bleeding index score	1.8	1.8	1.7	1.7
minor bleed* (%)	3.0	3.0	3.0	3.0
major bleed* (%)	3.0	3.0	3.0	3.0

HD hemodialysis; BP blood pressure


*occurring in the previous 30 days

Supplemental Figure 1: Point prevalence (95% confidence interval) of dabigatran and rivaroxaban among anticoagulated chronic hemodialysis patients with atrial fibrillation


Supplemental Figure 2: Point prevalence (95% confidence interval) of dabigatran among anticoagulated chronic hemodialysis patients with atrial fibrillation, by drug dose

Supplemental Figure 3: Point prevalence (95% confidence interval) of rivaroxaban among anticoagulated chronic hemodialysis patients with atrial fibrillation, by drug dose

Supplemental Figure 1



Supplemental Figure 2



Supplemental Figure 3

